An emergency department (ED)-focused, specialty pharmacist–led program for managing hepatitis C virus (HCV) at the University of Kentucky (UK) achieved more than a sixfold increase in direct-acting antiviral (DAA) treatment and avoided time-to-treatment delays that sometimes exceeded one year prior to the program’s launch, leaders of the initiative reported at ASHP Pharmacy Futures 2024, in Portland, Ore.
Despite the advent of curative DAA therapies for HCV beginning in